United Therapeutics SG&A decreased by 3.4% to $184.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.2%, from $170.10M to $184.10M. Over 3 years (FY 2022 to FY 2025), SG&A shows an upward trend with a 16.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $112.80M | $109.10M | $79.00M | $141.50M | $98.40M | $163.20M | $87.30M | $130.00M | $127.60M | $132.20M | $144.40M | $177.60M | $219.20M | $168.50M | $170.10M | $212.50M | $182.60M | $190.60M | $184.10M |
| QoQ Change | — | -3.3% | -27.6% | +79.1% | -30.5% | +65.9% | -46.5% | +48.9% | -1.8% | +3.6% | +9.2% | +23.0% | +23.4% | -23.1% | +0.9% | +24.9% | -14.1% | +4.4% | -3.4% |
| YoY Change | — | — | — | +25.4% | -9.8% | — | +10.5% | -8.1% | +29.7% | -19.0% | +65.4% | +36.6% | +71.8% | +27.5% | +17.8% | +19.7% | -16.7% | +13.1% | +8.2% |
Range$79.00M – $219.20M
CAGR+11.5%
Avg YoY Growth+18.1%
Median YoY Growth+17.8%
SG&A at Other Companies
Frequently Asked Questions
- What is United Therapeutics's sg&a?
- United Therapeutics (UTHR) reported sg&a of $184.10M in Q1 2026.
- How has United Therapeutics's sg&a changed year-over-year?
- United Therapeutics's sg&a increased by 8.2% year-over-year, from $170.10M to $184.10M.
- What is the long-term trend for United Therapeutics's sg&a?
- Over 3 years (2022 to 2025), United Therapeutics's sg&a has grown at a 16.2% compound annual growth rate (CAGR), from $482.10M to $755.80M.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.